Adverse events of glucocorticoids during treatment of rheumatoid arthritis: Lessons from cohort and registry studies

Rheumatology (United Kingdom)

Volumn 55, Issue , 2016, Pages ii3-ii5

  Bijlsma, Johannes W J ^a   Buttgereit, Frank ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adverse events; Cardiovascular disease; Glucocorticoids; Infections; Rheumatoid arthritis

Indexed keywords

GLUCOCORTICOID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DISEASE REGISTRY; ENDOCRINE DISEASE; EYE DISEASE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; LOW DRUG DOSE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN DISEASE; BONE NECROSIS; DIABETES MELLITUS; DISEASE ACTIVITY; DOSE RESPONSE; EDEMA; GASTROINTESTINAL SYMPTOM; HYPERTENSION; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MORTALITY; MYOPATHY; OSTEOPOROSIS; RISK BENEFIT ANALYSIS; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; REGISTER; RISK ASSESSMENT;

ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; GLUCOCORTICOIDS; HUMANS; MORTALITY; REGISTRIES; RISK ASSESSMENT;

EID: 85027287919     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew344     Document Type: Article

References (11)

1. Boers M, Kirwan JR, Bijlsma JWJ. American College of Rheumatology treatment guidelines continue to omit guidance on glucocorticoids; comment on the article by Singh et al. Arthritis Care Res 2012;64:1622.
2. StrehlC, BijlsmaJW, deWitMet al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoint from an EULAR task force. Ann Rheum Dis 2016;75:952-7.
3. Hoes JN, Jacobs JW, Boers M et al. EULAR evidencebased recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66:1560-7.
4. Buttgereit F. Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis? Ann Rheum Dis 2011;70:1881-3.
5. Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med 1953;249:553-6.
6. Bjornadal L, Baecklund E, Yin L et al. Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden. J Rheumatol 2002;29:906-12.
7. Krause D, Schleusser B, Herborn G et al. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000;43:14-21.
8. Listing J, Kekow J, Manger B et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF inhibitors and rituximab. Ann Rheum Dis 2015;74:415-21.
9. Bakker MF, Jacobs JWG, Welsing PM et al. Low-dose prednisone inclusion in a methotrexate-based tight control strategy for early RA: a randomized trial. Ann Intern Med 2012;156:329-39.
10. del Rincó n I, Battafarano DF, Restrepo JF et al. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2014;66:264-72.
11. Duru N, van der Goes MC, Jacobs JWG et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72:1905-13.